Hold the Chemo

TAILORx trial researchers say that most women with early stage breast cancer who receive a low recurrence risk score on Genomic Health's Oncotype DX test do well on hormonal therapy alone and are disease-free after five years, as GenomeWeb has reported.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

Researchers find that a personalized medicine approach could help people who experience pain while taking statins, New Scientist reports.

US National Science Foundation is continuing its responsible research conduct training policy despite its flaws, ScienceInsider reports.

A CRISPR-themed meeting explored how the tool could and should be used, Wired reports.

In Science this week: database of proteins' effects on cancer, targeted error correction sequencing, and more.